World's Best Scientists 2026 revealed!
Svetomir N. Markovic

Svetomir N. Markovic

D-Index & Metrics

Medicine

D-Index
84
Citations
21433
World Ranking
15281
National Ranking
7709

Overview

Svetomir N. Markovic is affiliated with the Mayo Clinic in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a strong focus on Oncology, Immunology, and Molecular Biology as key subfields of study. Additional areas of investigation include Pulmonary and Respiratory Medicine and Hematology.

The main topics covered in their research encompass:

  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • CAR-T cell therapy research
  • Melanoma and MAPK Pathways
  • Cutaneous Melanoma Detection and Management
  • Immune Cell Function and Interaction
  • Extracellular vesicles in disease

Markovic has published frequently in several scientific journals. The venues with the highest number of their publications include:

  • Journal of Clinical Oncology
  • Blood
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer
  • bioRxiv (Cold Spring Harbor Laboratory)

Among recent papers attributed to Markovic, notable works include:

  • "Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy" (2020), published in Journal of Experimental & Clinical Cancer Research
  • "Neurologic autoimmunity and immune checkpoint inhibitors" (2020), published in Neurology
  • "Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials" (2020), published in JAMA Network Open
  • "International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors" (2023), published in International Forum of Allergy & Rhinology
  • "Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events" (2021), published in Kidney International Reports

Collaborative work is a consistent component of Markovic's research activities. Frequent co-authors include:

  • Matthew S. Block
  • Lisa A. Kottschade
  • Wendy K. Nevala
  • Robert R. McWilliams
  • Haidong Dong

Best Publications

  • Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

    Edward L. Korn;Ping Yu Liu;Sandra J. Lee;Judith Anne W. Chapman

  • Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis

    Svetomir N. Markovic;Lori A. Erickson;Ravi D. Rao;Robert R. McWilliams

  • Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

    Yucai Wang;Shouhao Zhou;Shouhao Zhou;Fang Yang;Xinyue Qi

  • Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.

    Luis F. Porrata;Morie A. Gertz;David J. Inwards;Mark R. Litzow

  • Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

    Shernan G. Holtan;Douglas J. Creedon;Paul Haluska;Svetomir N. Markovic

  • Neurological Complications Associated With Anti-Programmed Death 1 (PD-1) Antibodies.

    Justin C. Kao;Bing Liao;Svetomir Nenad Markovic;Christopher Jon Klein

  • Therapy for metastatic melanoma: the past, present, and future

    Laura Finn;Svetomir N Markovic;Richard W Joseph

  • B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders.

    Ryan A. Wilcox;Andrew L. Feldman;David A. Wada;Zhi Zhang Yang

  • Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma

    Luis F. Porrata;Kay Ristow;Joseph P. Colgan;Thomas M. Habermann

  • Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.

    Filippo Galli;Jesus Vera Aguilera;Belinda Palermo;Svetomir N. Markovic

  • Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.

    Stephen M. Ansell;Thomas E. Witzig;Paul J. Kurtin;Jeff A. Sloan

  • Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma

    Wendy K. Nevala;Celine M. Vachon;Alexey A. Leontovich;Christopher G. Scott

  • Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment

    Svetomir N. Markovic;Lori A. Erickson;Ravi D. Rao;Roger H. Weenig

  • Acquired C1 esterase inhibitor deficiency.

    Svetomir N. Markovic;David J. Inwards;Evangelos A. Frigas;Robert P. Phyliky

  • The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.

    R A Wilcox;K Ristow;T M Habermann;D J Inwards

  • Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.

    Domingo G. Perez;Vera J. Suman;Tom R. Fitch;Thomas Amatruda

  • BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

    Kevin B. Kim;Jeffrey A. Sosman;John P. Fruehauf;Gerald P. Linette

  • Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines

    Stephen M. Ansell;Robert A. Kyle;Craig B. Reeder;Rafael Fonseca

  • Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma.

    Evanthia Galanis;Svetomir N Markovic;Vera J Suman;Gerard J Nuovo

  • Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.

    Yiyi Yan;Anagha Bangalore Kumar;Heidi Finnes;Svetomir Nenad Markovic

Frequent Co-Authors

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in medicine but want alternative or accelerated paths, several online degrees can help you start a rewarding healthcare career. These programs offer flexibility and affordability, allowing students to study remotely and often at their own pace.

For those interested in pharmacy, a 3-year online pharmd program is a fast-track option compared to traditional routes. This degree is ideal for future pharmacists aiming for a doctoral credential while balancing work or family commitments.

If healthcare data and information systems appeal to you, consider earning an online mhi (Master’s in Health Informatics). Graduates play a key role in managing patient records and improving health delivery.

For those seeking a quick entry into the healthcare field, medical billing and coding classes online offer specialized training for administrative roles in hospitals and clinics.

Lastly, aspiring advanced practice nurses can enroll in cheap np programs to earn a Nurse Practitioner degree online. This enables you to provide primary care, even in underserved areas.

Best Scientists Citing Svetomir N. Markovic

Trending Scientists

Recently Published Articles